Drug Trial Radar · NCT02762253
Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.
Last checked: Nov 19, 2026Latest source record: May 5, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
320
Actual
Start
Sep 2012
Primary completion
Apr 2016
Study completion Apr 2016
Sponsor
- Lead sponsor
- Nvision Laser Eye CentersIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to assess the safety and effectiveness of photochemically induced collagen cross- linking (CCL) at irradiance of 18mW/cm2 in eyes with Keratoconus and Ecstasia.
Conditions
- Keratoconus
Interventions
Riboflavin dropsDrug
Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
Primary outcomes
What the sponsor says the trial is designed to measure.
- KeratometryTime frame: 6 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
NVISION Camarillo
Camarillo, California
NVISION Sacramento
Citrus Heights, California
NVISION Fullerton
Fullerton, California
NVISION Laguna Hills
Laguna Hills, California
NVISION Newport Beach
Newport Beach, California
NVISION Ontario
Ontario, California
NVISION La Jolla
San Diego, California
Berg Feinfield Vision Center
Sherman Oaks, California
NVISION Torrance
Torrance, California
NVISION Las Vegas
Las Vegas, Nevada
Teplick Custom Vision
Beaverton, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.